Drug Trial Radar · NCT03333928
A POC and Dose-Ranging Study of HTD1801 in PSC Patients
Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Feb 9, 2018
Primary completion
Apr 30, 2020
Study completion Aug 14, 2020
Sponsor
- Lead sponsor
- HighTide Therapeutics (Hong Kong) LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study was a dose-ranging, 18-week study comparing two doses of HTD1801 (500 mg BID and 1000 mg BID) to placebo in adult subjects with PSC.
Conditions
- Primary Sclerosing Cholangitis (PSC)
Interventions
HTD1801Drug
HTD1801 tablets, 250 mg
PlaceboDrug
tablets manufactured to mimic HTD1801 tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change in Serum Alkaline Phosphatase (ALP) From Baseline to Week 6 in Period 1Time frame: Baseline to Week 6
Locations
26 sites in 2 countries. Site status is shown where the registry gives one.
Arizona Liver Health
Chandler, Arizona
Arizona Liver Health
Tuscon, Arizona
Fresno Clinical Research Center
Fresno, California
Keck School of Medicine of USC
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
University of Colorado, Denver
Aurora, Colorado
South Denver Gastroenterology, PC
Englewood, Colorado
Yale School of Medicine
New Haven, Connecticut
Florida Research Institute
Lakewood Rch, Florida
University of Miami
Miami, Florida
Mercy Medical Center
Baltimore, Maryland
Walter Reed National Military Medical Center
Bethesda, Maryland
Michigan Medicine University of Michigan
Ann Arbor, Michigan
Gastrointestinal Associates
Flowood, Mississippi
Washington University School of Medicine
St Louis, Missouri
Mount Sinai - Icahn School of Medicine
New York, New York
Cumberland Research Associates
Fayetteville, North Carolina
Wake Forest Baptist Health
Winston-Salem, North Carolina
Gastro One
Germantown, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Pinnacle Clinical Research
Austin, Texas
Pinnacle Clinical Research
San Antonio, Texas
Swedish Medical Center
Seattle, Washington
University of Washington
Seattle, Washington
Aspen Woods Clinic
Calgary, Alberta, Canada
Toronto Centre for Liver Disease, Toronto General Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.